Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Prothena Corp Public Ltd Co

NASDAQ: PRTA · Life Sciences · 11 alerts · CIK 1559053

Share price
$7.97Close, Nov 16
Market cap
$409M
Shares outstanding
51.35MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Prothena Corp Public Ltd Co filings on SEC EDGAR ↗

2:45 PM ET Form 4
Insider Buying

Prothena Corp Public Ltd Insider William P. Scully Buys $1.19M of Stock

William P. Scully bought 140,000 shares of Prothena Corp Public Ltd Co at $8.53 a share, worth $1.19M in total on Nov 9, 2026. Shares held after the trade: 977,000 (+16.7%).

Value
$1.19M
Shares
140,000
Price
$8.53
Holding change
+16.7%
Trade date
Nov 9, 2026
4:16 PM ET 10-Q
Financial Results

Prothena Corp Public Ltd Q3 2026 Results: Net Loss of $16.5M, Loss Narrows

Prothena reported total revenue of $52.7 million for the first nine months of 2026, driven primarily by $50.1 million from license and intellectual property revenue. The company significantly reduced its operating expenses to $62.6 million compared to $200.1 million in the prior year period, resulting in a narrowed net loss. As of September 30, 2026, the company maintained a cash and cash equivalents balance of $271.4 million.

Key figure
Net loss $16.5M
4:09 PM ET 8-K
Financial Results

Prothena Corp Public Ltd Financial Results

Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher Barrett’s Esophagus test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.

Term
Q3 2026

“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”

Derek Maetzold, president and chief executive officer of Castle Biosciences

“Overall, our third-quarter results reflect the strength of our portfolio, consistent execution and continued progress toward our long-term growth objectives. I want to thank the entire Castle team for their dedication, hard work and unwavering commitment to improving patient care.”

Derek Maetzold, president and chief executive officer of Castle Biosciences
4:04 PM ET 8-K
Deal Termination

Prothena Corp Public Ltd Deal Termination with Bristol Myers Squibb

Bristol Myers Squibb (BMS) has terminated its exclusive global license agreement for PRX019 with Prothena following an internal strategic review. As a result of the termination, effective January 28, 2027, Prothena is no longer eligible to receive up to $617.5 million in potential development, regulatory, and sales milestones. BMS will continue to develop moponetug (PRX005) under a separate ongoing collaboration agreement.

Counterparty
Bristol Myers Squibb
4:20 PM ET Form 4
Insider Buying

Prothena Corp Public Ltd Insider William P. Scully Buys $1.22M of Stock

William P. Scully bought 150,000 shares of Prothena Corp Public Ltd Co at $8.07 to $8.19 a share (average $8.15) in 2 transactions, worth $1.22M in total between Oct 22, 2026 and Oct 23, 2026. Shares held after the trade: 1,187,000 (+4.4%).

Value
$1.22M
Shares
150,000
Average price
$8.15
Holding change
+4.4%
Trade date
Oct 22, 2026 to Oct 23, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.